Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients.
about
Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.Standard First-Line Chemotherapy for Metastatic Gastric Cancer in Japan Has Met the Global Standard: Evidence From Recent Phase III Trials.Efficacy of S-1 in colorectal cancer.Phase II study of S-1 in patients with advanced biliary tract cancer.Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study.Race does not explain genetic heterogeneity in pharmacogenomic pathways.Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.Predictive factors for ocular complications caused by anticancer drug S-1.Prediction discrepancies for the evaluation of nonlinear mixed-effects models.Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.Feasibility and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic or recurrent breast cancer.Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling.Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study
P2860
Q33566877-44E19AFB-4058-492A-B400-A0FA2F716F52Q34395983-A7361CFF-AB06-4ED5-92BA-5B2566E2398BQ34429445-01409A86-C8E1-4EE4-A522-C886DAD88EFAQ36696249-6EDDCC36-0139-4433-956B-DB28D5F30A41Q36747438-F690F39C-9C04-4AF1-89AC-CB19264F0A3CQ36999930-49FB6AB0-704B-495E-AFC3-3BC3F75179F0Q37076675-A9AC4ACE-80D3-466C-9E93-7D1E8E60891BQ37247762-FA5AAB78-E773-476F-BE5B-AB912C4458ECQ40932785-F3F85FC2-D934-4B26-A995-47C01005A21CQ41676533-7F34072F-399E-4DEF-8714-85B7306AF728Q42117272-284E1068-BFE7-4F70-892F-04C63C669FA8Q43230727-9CA96FA2-C2EA-47FC-A176-FEA1909D4DA6Q44309547-F63555A4-D4B1-40EE-BF7F-F055FDE1351CQ50208128-E7D7A20B-00E4-4438-B6AE-B7D6DFF5C4B3Q57069558-159336A2-875F-4717-AFC4-B0BAD0087737
P2860
Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Comparison of the pharmacokine ...... Western and Japanese patients.
@ast
Comparison of the pharmacokine ...... Western and Japanese patients.
@en
type
label
Comparison of the pharmacokine ...... Western and Japanese patients.
@ast
Comparison of the pharmacokine ...... Western and Japanese patients.
@en
prefLabel
Comparison of the pharmacokine ...... Western and Japanese patients.
@ast
Comparison of the pharmacokine ...... Western and Japanese patients.
@en
P2093
P2860
P356
P1476
Comparison of the pharmacokine ...... Western and Japanese patients.
@en
P2093
Emmanuelle Comets
Jantien Wanders
Kazumasa Ikeda
Paulo Hoff
Pierre Fumoleau
Yusuke Tanigawara
P2860
P2888
P304
P356
10.1023/A:1026142601822
P577
2003-08-01T00:00:00Z
P6179
1011031340